AVTX news

Latest 2 stories · newest Aug 6, 2026

AVTX

Avalo Therapeutics starts Phase 3 in 2027, cash runway extends to 2029

Avalo Therapeutics reports 2026 Q2 financials with $472.2M cash and initiates a Phase 3 HS program in 2027, driving significant investor interest in its long-acting IL-1beta pipeline.

Earnings Aug 6, 2026 sentiment 0.00 SEC filing ↗

AVTX

Avalo Therapeutics advances AVTX-010, long-acting anti-IL-1β antibody

Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody designed for hidradenitis suppurativa and other inflammatory disorders, with IND submission planned for H1 2027. The pipeline expansion builds on positive Phase 2 data for lead asset abdakibart and…

Regulatory Jun 16, 2026 sentiment +0.75 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same AVTX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/AVTX/newsSTART FREE